Subject Index

Accell® gene delivery system, 282
Adeno-associated virus promoters, Rep proteins and, 99
Adeno-associated virus-based vectors, 100
Adenovirus
  gene therapy and, 95
  recombinant, 236
Adenovirus vectors, 96
Adjuvant role of DNA, 74
African green monkeys, rev DNA vaccine responses in, 205
AIDS, nucleic acid vaccines against, 182
Alphavirus, 261
Anti-DNA
  pathogenicity of, 153
  specificity of, 154
Anti-DNA antibodies, possible induction of, 166
Anti-viral vaccines, plasmid vectors as, 77
Antigen-presenting cells, 69
Application, practical, in genetics and vaccinology, 2
Autoaggression, long-term expression of foreign antigen and, 166
Autoimmunity, long-term expression of foreign antigen and, 166

Bacterial DNA
  antigenicity of, 155
  immunogenicity of, 156
  mitogenicity of, 158
Beta-galactosidase
  intramuscular injection and, 69
  reporter gene function of, 127
Bupivicaine, reporter gene expression and, 44

Cancer, human, direct gene transfer and, 227
Cationic lipid, 126
$CD4^+$ T lymphocytes, protective, 90
$CD8^+$ T lymphocytes, protective, 89
Cell culture vaccinology, mammalian, 7
Cell-mediated immunity, 53
Childhood immunization, DNA vaccines and, 85
Chloramphenicol acetyl transferase (CAT), reporter gene function of, 127
Chromosome
  foreign DNA integration into, 143
  integration of DNA into, 173
Clinical studies, HIV-seropositive subjects and, 112
Clinical trials, European Union and, 180
CMVint construct, 128
Contamination, primary cell cultures and, 8
Continuous cell lines, 10
Cross clade cytotoxic T cell responses, 189
Cross-strain protection, 16
Crossreactive cytotoxic T lymphocytes, 109
Cynomologous monkeys, immune responses in, 190
Cystic fibrosis transmembrane regulator (CFTR), 135
Cytofectin, 130
Cytokine
  bacterial DNA and, 160
  ELISPOT assay and, 58
Cytokine profiles, DNA-mediated immunization and, 69
Cytoplasmic amplification, 263
Cytotoxic T lymphocyte
  HIV immunotherapy and, 105
  intramuscular injection of plasmid DNA and, 42
  nucleoprotein and, 16
  SIV and, 210
Cytotoxic T lymphocyte activity, pSV3-neo induced, 246
Cytotoxic T lymphocyte response
  exogenous hepatitis B surface antigen and, 68
  HIV polynucleotide vaccination and, 198

Dendritic cells, 71
Diagnosis, gB-specific antibodies and, 60
[N,N′,N′-(Dimethylaminoethane)carbamoyl] cholesterol (DC-cholesterol), 136
  advanced melanoma and, 228
1,2-Dimyristyloxypropyl-3-dimethylhydroxy-ethyl ammonium bromide (DMRIE), 136
  advanced melanoma and, 229
Dioleoylphosphatidylethanolamine (DOPE), 129
  advanced melanoma and, 228
2,3-Dioleyloxy-N-{2-(spermine-carbox-amido)ethyl}-N,N-dimethyl-1-propanaminium (DOSPA), 134
N[1-(2,3-Dioleyloxy)propyl]-N,N,N-trimethyl ammonium bromide (DOTMA), 136
Direct gene transfer
  human cancer and, 227
  plasmid DNA used for, 21
DNA, immunogenicity of, 153

DNA expression vectors, HBV envelope protein and, 66
DNA immunization, many species tested for, 51
DNA plasmids, reporter genes and, 15
DNA vaccination, anti-DNA induction and, 157
DNA vaccine
  idiotypic, 217
  naked DNA as, 213
  overview of, 15
  release of proteins encoded by, 220
  serum antibodies induced by, 218
  vaginal mucosa and, 265
DNA vectors, layered amplification of gene expression and, 261
DNA-based immunization, hepatitis B virus and, 23
DNA-mediated immunization, hepatitis B surface antigen and, 64

Efficacy of DNA vaccines
  avenues to improve, 82
  initial demonstration of, 16
ELISPOT assay, 58
Endotoxin-free DNA production, 272
Eukaryotic genome, natural DNA transposition in, 141
Eukaryotic layered vector system (ELVS™), 261
European Agency for the Evaluation of Medicinal Products (EMEA), 181
European Union, marketing authorization in, 178
Exogenous hepatitis B surface antigen, CTL and, 68
Exogenous protein, MHC class I presentation and, 74

Foreign DNA, risk potential of, 140

Gene gun
  Accell®, 282
  SIVmac innoculations and, 209
Gene therapy
  direct injection of polynucleotides and, 232
  glycosylated steroids and polyamines and, 268
  human, plasmid DNA and, 271
Gene-deleted vaccines, 48
Genetic immunization, 17
Glycosteroids, 268
Glycosylation, expression of parasite antigens and, 164
gp120 DNA
  mice and, 201
  monkeys and, 204
gp160/rev DNA, mice and, 203
Guidelines on quality control, 167

Hayflick's cell strains, 9
Helper T cell response, HIV polynucleotide vaccination and, 198
Hemagglutination inhibition (HI), 119
Hemagglutinin (HA) DNA, 120
Hepatitis, chronic, 65
Hepatitis B surface antigen, 65
Hepatitis B virus
  Accell® gene delivery system and, 282
  DNA-based immunization to, 23
  DNA-mediated immunization and, 65
Herpesvirus gD vaccine, 49
HIV immunotherapy, retroviral vectors for, 106
HIV polynucleotide vaccination, CTL and helper T cell responses following, 198
HIV regulatory genes, nucleic acid vaccination with, 278
HIV-1 gp120, 257
HIV-1 gp160 constructs, 188
HIV-seropositive subjects, retroviral vector immunization and, 111
Host cell genome, integration into, 30
Humoral immune response, naked DNA and, 119
(+/−)-N-(2-Hydroxyethyl)-N,N-dimethyl-2,3-bis(dodecyloxy)-1-propanaminium bromide (DLRIE), 135
Hyperimmunity, long-term expression of foreign antigen and, 166

Idiotypic antigens, lymphoma and, 216
Idiotypic determinants, clonal Ig and, 212
Idiotypic protein, $CD4^+$ T cells and, 221
Immune activation, entrainment and, 73
Immune effector mechanisms, response to DNA vaccine and, 81
Immune entrainment, amplification of immune response and, 71
Immune response
  adenovirus and, 237
  nature of, 174
Immunity, broad-based, 119
Immunotherapeutic intervention, DNA-mediated immunization and, 74
In vivo challenge system, 189
Induced mutation frequency, risk assessment of, 36
Inflammatory environment, 71

Influenza, increase efficacy of vaccine for, 15
Influenza A virus, intramuscular injection of plasmid DNA and, 41
Insertion, three ways of, 165
Insertional mutagenesis, transposable elements and, 144
Integration, host cell genome and, 30
Integration of DNA, host chromosome and, 173
Interferon-γ, induction of, 159
Intramuscular injection, hepatitis B surface antigen and, 68

Large tumor antigen (T-ag), 241
Life cycle, malaria parasite and, 89
Lipid emulsion, synthetic oligonucleotide and, 252
Lipofectamine (DOSPA), 134
Lipofection, 126
Long-term expression, side effects of, 175
Luciferase, reporter gene function of, 127
Lymphoma, recombinant scFv protein and, 214
Lymphopoietic tissue, human, HIV and, 281

M. tuberculosis infection, mouse model of, 44
Major histocompatibility complex (MHC) molecules
  DNA-mediated immunization and, 70
  interactions of TCR with, 15
Major histocompatibility complex (MHC) proteins, fresh tumors and, 227
Mammalian cell substrates, development and acceptance of, 7
Marketing authorization, European Union and, 178
Maternal transfer of antibodies, efficacy of DNA vaccines and, 83
Mice
  gp120 DNA-mediated antibody responses in, 201
  gp160/rev DNA vaccine responses in, 203
  HBsAg DNA vaccine and, 282
  rev DNA vaccine responses in, 205
Monkeys, HBsAg DNA vaccine and, 282

Naked DNA, 18
  immunization against viral proteins with, 117
  intramuscular immunization with, 40
  layered vector system and, 261
  S. typhi ompC gene and, 285
Natural DNA transposition, eukaryotic genome and, 141
neu/HER-2 cDNA, pregnancy loss and, 274
Neutralizing antibody, SIV and, 210
Nonhuman primates, immune response induction in, 110
Nonleukocyte cells, immune entrainment and, 73
Novel vaccines, 48
Nucleic acid vaccines, 17
  potential advantages of, 170
Nucleoprotein (NP) DNA, 120
Nucleoprotein gene, 16

Oligonucleotide carrier, 252
ompC gene, 286
Outer membrane proteins, 285

Packaging cell, HIV immunotherapy and, 107
Particle-mediated DNA immunization, 282
Passive immunization, efficacy of DNA vaccines and, 83
pCDNA3-neuNT, 274
pCIS-CAT construct, 128
Pigs, HBsAg DNA vaccine and, 282
Plasmid DNA
  direct gene transfer and, 21
  human gene therapy and, 271
Plasmid vectors
  anti-viral vaccines and, 77
  pCIS-CAT and CMVint as, 128
Plasmodium infection, nucleic acid malaria vaccines and, 88
Plasmodium yoelii circumsporozoite protein (PyCSP), 89
Plasmodium yoelii hepatic/erythrocytic protein 17 (PyHEP17), 90
pM160-Z6 immune monkey serum, anti-viral activity of, 191
Polymerase chain reaction (PCR), purified host genomic DNA and, 31
Polynucleotide expression vectors, 17
Polynucleotide vaccines, 17
Preclinical development, European Union and, 180
Preerythrocytic stage antibodies, 90
Pregnancy loss, neu/HER-2 cDNA and, 274
Protection, SIV and, 210
Protein expression, duration of, 73
Protooncogenes, activation of, 147
pSV3-neo induced humoral immunity, 245
Purification, host genomic DNA and, 30

QIAGEN procedure, 272
Quality, plasmid DNA and, 271
Quality control, guidelines for, 167

Rabbit papilloma virus, 41
Rabies virus G protein, DNA vaccines expressing, 80
Regenerating muscle, gene transfer in, 23
Regulatory issues
  DNA vectors and, 6
  use of DNA vaccines and, 170
Regulatory perspectives, 18
Rep proteins, adeno-associated virus and, 99
Reporter gene, luciferase as, 127
Responders, poor, 65
Retroviral vector, HIV immunotherapy and, 105
Rev DNA
  African green monkeys and, 205
  mice and, 205
Rhesus monkeys, gp120 DNA vaccine responses in, 204
Risk assessment, host genomic DNA and, 36
Risk potential, foreign DNA and, 140
RNA vaccination, 255
RNA vaccines, 18

Safety
  DNA vectors and, 1
  integration into genome and, 30
  mammalian cell cultures and, 8
Saline injections, 209
Salmonella typhi, 285
Semliki Forest virus (SFV)-RNA, 255
Severe combined immunodeficiency (SCID) mice, HIV regulatory genes and, 281
Simian immunodeficiency virus, HIV-2 and, 186
Simian immunodeficiency virus macaque (SIVmac), 209
Simian virus 40 (SV40), large tumor antigen of, 241
Single chain Fv (scFv) sequences, 215
Site, specific, of viral DNA integration, 98
Site-specific integration, targeting and tethering, 149
Skeletal muscle, plasmid DNA in, 22
Subunit vaccines, 48
Systemic lupus erythematosus (SLE), serology of, 152

T cell response
  DNA-mediated immunization and, 65
  naked DNA and, 121
Th1 cytokines, 70
Therapeutic vaccination, DNA-mediated immunization and, 64
Tolerance, long-term expression of foreign antigen and, 166
Transduced cells, HIV immunotherapy and, 106
Transfection
  cationic lipid-mediated, 126
  glycosteroid-polyamine compounds and, 268
Transfection of muscle fibers, 72
Transformational event, extraneous DNA and, 165
Tumor suppressor genes, inactivation of, 147

VIJneo-NP plasmid, PCR amplification and, 32
Vaccine vector, adenovirus as, 97
Vaginal mucosa, 265
Vector localization, HIV immunotherapy and, 109
Vector vaccines, ultimate simplicity in, 4
Vectors, DNA, safety and, 1
Viral DNA integration, specific site of, 98
Viral proteins, naked DNA and, 117
Viral vectorology, DNA vectorology and, 3
Virally induced tumors, nucleic acid vaccination against, 241

World Health Organization Biologicals Unit, 168
World Wide Web, 64

Index of Contributors

Agadjanian, M., 186–197
Amici, A., 274–277
Anderson, D. J., 265–267
Arthos, J., 209–211
Ashworth, L. J., 212–226
Axelrod, H., 268–270

Babiuk, L. A., 47–63
Babu, S., 268–270
Baca-Estrada, M., 47–63
Banks, T. A., 261–264
Belli, B. A., 261–264
Berns, K. I., 95–104
Bishop, K., 227–231
Borrebaeck, C. A. K., 278–281
Boyer, J., 186–197
Bravo, L. M., 252–254
Bright, R. K., 241–251
Bruck, C., 255–256
Brumm, D., 261–264
Bydlowski, S. P., 252–254

Cambridge, G., 257–260
Carrano, R., 186–197
Chada, S., 261–264
Chang, A. E., 227–231
Chang, S. M. W., 261–264
Cheng, S. H., 126–139
Cichutek, K., 178–185
Cohen, J., 255–256
Concetti, A., 274–277
Coney, L., 186–197
Cox, G., 47–63
Crowley, S. D., 152–163

Dalemans, W., 255–256
Dang, K., 186–197
Davies, M-E., 198–208
Davis, H. L., 21–29, 64–76
de Souza, B., 257–260
Debes, A. A., 252–254
Deck, R. R., 117–125
Delers, A., 255–256
Delmelle, C., 255–256
Delves, P. J., 257–260
Denamur, F., 255–256
Dériaud, E., 64–76
DeWitt, C. M., 117–125
Donnelly, J. J., 40–46, 117–125
Doolan, D. L., 88–94
Driver, D. A., 261–264
Dubensky, T. W., Jr., 261–264

Ertl, H. C. J., 77–87

Felgner, P. L., 126–139, 227–231
Francotte, M., 255–256
Freed, D. C., 198–208
Fuller, D. H., 282–284
Fuller, J. T., 282–284

Galpin, J., 105–116
Gilbert, L., 186–197
Giraud, C., 95–104
González, C. R., 285–288
Gordon, D., 227–231
Gowda, K., 88–94
Gramzinski, R., 88–94
Griffiths, E., 164–169

Halpern, M. D., 152–163
Haubrich, R., 105–116
Hawkins, R. E., 212–226
Haynes, J. R., 209–211, 282–284
He, Z., 77–87
Hedstrom, R. C., 88–94
Hilleman, M. R., xi–xiv, 1–14
Hinkula, J., 278–281
Hobart, P., 88–94
Hoffman, S. L., 88–94

Isibasi, A., 285–288

Johnson, E., 209–211
Jolly, D. J., 105–116, 261–264

Kakarla, R., 268–270
Kass-Eisler, A., 232–240
Kennedy, R. C., 241–251
King, C. A., 212–226
Klonisch, T., 257–260
Kogan, N., 268–270
Kumar, S., 212–226
Kurth, R., xi–xiv, 140–151

Latham, E. M., 261–264
Leclerc, C., 64–76
Ledwith, B. J., 30–39
Leinwand, L. A., 232–240
Letvin, N. L., 209–211
Lewis, P. J., 47–63
Li, K., 232–240
Liu, M. A., xi–xiv, 15–20, 40–46, 117–125, 198–208
Livingston, J. B., 265–267

Longley, C., 268–270
López-Hernández, M. A., 285–288
López-Macías, C., 285–288
Lu, S., 209–211, 265–267
Lund, T., 257–260

Manam, S. V., 30–39
Manson, K., 209–211
Manthorpe, M., 126–139
Maranhão, R. C., 252–254
Margalith, M., 88–94
Marquet, M., 227–231
Marshall, J., 126–139
Matear, P., 257–260
McCabe, D., 282–284
McCallus, D., 186–197
Mento, S. J., 105–116, 261–264
Merritt, J., 105–116
Merva, M., 186–197
Meykens, R., 255–256
Michel, M-L., 21–29
Midha, S., 268–270
Minor, P. D., 170–177
Moelling, K., 186–197
Montefiori, D., 209–211
Moritz, P., 271–273
Mullins, J. I., 209–211
Mustafa, F., 209–211

Nabel, E. G., 227–231
Nabel, G. J., 227–231
Nichols, W. W., 30–39
Norman, J., 88–94

Ortiz-Navarrete, V., 285–288

Peet, N., 257–260
Perry, H. C., 198–208
Petrelli, C., 274–277
Pisetsky, D. S., 152–163
Polo, J. M., 261–264

Reich, C., 152–163
Reimann, J., 64–76
Robinson, H. L., 209–211, 265–267

Santoro, J. C., 209–211
Schirmbeck, R., 64–76
Schleef, M., 271–273
Schorr, J., 271–273
Schwartz, S., 278–281
Seddon, T., 271–273
Sedegah, M., 88–94
Shearer, M. H., 241–251
Shiver, J. W., 198–208
Sofia, M., 268–270
Srikantan, V., 186–197
Ståhle, E. L., 278–281
Stevenson, F. K., 212–226
Sukhu, L., 126–139

Thiriart, C., 255–256
Thompsett, A., 212–226
Tikoo, S. K., 47–63
Troilo, P. J., 30–39
Tsai, Y. J., 126–139

Ugen, K., 186–197
Ulmer, J. B., 40–46, 117–125

Van Drunen Littel-van den Hurk, S., 47–63
Veenstra, S., 255–256
Venanzi, F. M., 274–277
Verma, P., 77–87
Vinagre, C. G., 252–254
Vyakarnam, A., 257–260

Wahren, B., 278–281
Walker, S., 268–270
Wang, B., 186–197
Wang, H., 88–94
Warner, J. F., 105–116
Weiner, D. B., 186–197
Whalen, R. G., 21–29, 64–76
Wheeler, C. J., 126–139
Widera, G., 282–284
Wierichs, L., 268–270
Wigzell, H., 278–281
Wilkinson, L., 257–260
Williams, W. V., 186–197
Winsink, J., 209–211
Wyand, M., 209–211

Xiang, Z. Q., 77–87

Yang, Z-Y., 227–231
Yasutomi, Y., 209–211

Zhu, D., 212–226